On a year-over-year basis, Indian revenue showed 18% growth to Rs1,093cr. However, US sales fell -29% to Rs266cr due to elevated price pressures amid generic competition in the US markets. Other key markets such as Germany and Brazil grew 5% and 9% respectively. CRAMS business grew 6% year-on-year.
For the June 21 quarter, Torrent Pharma reported gross margins of 72.4% and EBITDA margins of 34%. EBITDA increased 8% YoY to Rs717cr in the June 21 quarter. PCPM for the quarter was Rs. 10 lakhs and Torrent had a MR strength of 3,600. As of June 21, Torrent has 54 ANDAs pending approval with the USFDA, while Torrent has received 7 interim approvals.
Net profit for the June 21 quarter increased 2.8% to Rs330cr on stable EBITDA margins and gross margins in the India business. Net margins for the first quarter were 15.46% compared to 15.61% in the June 20 quarter and 16.73% in the sequential quarter of March 21.
Financial Highlights for June 21 Compared YoY and Sequentially
| Torrent Pharma | |||||
| Rs in Crore | June 21 | June 20th | I AND | Mar-21 | QOQ |
| Total revenue (Rs cr) | 2134 ARS | 2056 โน | 3.79% | 1937 โน | 10.17% |
| Operating profit (Rs cr) | $ 512 | โน 500 | 2.40% | $ 417 | 22.78% |
| Net profit (Rs cr) | 330 โน | $ 321 | 2.80% | $ 324 | 1.85% |
| Diluted EPS (Rs) | $ 19.53 | $ 18.98 | $ 19.16 | ||
| OPM | 23.99% | 24.32% | 21.53% | ||
| Net margins | 15.46% | 15.61% | 16.73% |
Related Tags:
